Psychedelic Research Links November 2023
Published on 11/7/2023
This is all the other psychedelic research that came out in November 2023. These papers don’t (yet) have their own page in our database.
You can find all the added papers in our Papers Database.
Related Papers
In Rodents
- Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney’s lesions (in rats, “In contrast to S-ketamine- and MK-801-treated animals, we did not detect any HSP70-positive neurons in retrosplenial cortex of rats treated with psilocybin. Our results suggest that psilocybin might be safer for clinical use compared to S-ketamine regarding neuronal damage.“)
- Role of the gut-brain axis via the subdiaphragmatic vagus nerve in stress resilience of 3,4-methylenedioxymethamphetamine in mice exposed to chronic restrain stress (in mice, “… gut-brain axis via the subdiaphragmatic vagus nerve might contribute to the stress resilience of MDMA.“)
- Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice (in mice, “Our results provide preclinical evidence of the anxiolytic- and antidepressant-like effects of the P. cubensis mushroom without producing neurotoxicity after enteral or parenteral administration, where psilocybin and psilocin were identified mainly after AQ extraction.“)
- Microdosing ketamine in Drosophila does not inhibit SERT like SSRIs, but causes behavioral changes mediated by glutamate and serotonin receptors (in larvae!, “At microdoses, ketamine did not affect serotonin, which was different from SSRIs. However, higher doses inhibited dSERT.“)
- Reduction of BDNF Levels and Biphasic Changes in Glutamate Release in the Prefrontal Cortex Correlate with Susceptibility to Chronic Stress-Induced Anhedonia (in rats, “Reductions of BDNF levels may be key neurobiological markers of susceptibility to stress-induced anhedonia.“)
- Modulation of DOM-Induced Head-Twitch Response by mGluR2 Agonist/Inverse Agonist is Associated with 5-HT2AR-Mediated Gs Signaling Pathway (in mice, “The results showed that DOM-induced HTR in mice was dose-dependently inhibited by LY379268, LY354740, and LY404039, while it was dose-dependently enhanced by LY341495.”)
- Low-dose Esketamine suppresses NLRP3-mediated apoptotic and pyroptotic cell death in microglial cells to ameliorate LPS-induced depression via ablating GSK-3β (in mice, “ Taken together, low-dose Esketamine ameliorated LPS-induced depressive symptoms in mice through regulating the GSK-3β/NLRP3 pathway, and our work suggested that appropriate doses of Esketamine were essential for the treatment of depression in clinic.“)
Chemistry
- N, N-dimethyltryptamine forms oxygenated metabolites via CYP2D6 – an in vitro investigation (in cells, “DMT was rapidly metabolised by CYP2D6, while stable with all other investigated CYP enzymes.“)
- Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders (creation and testing of psilocybin-like molecules by Enveric Biosciences team)
- Novel harmine derivatives as potent acetylcholinesterase and amyloid beta aggregation dual inhibitors for management of Alzheimer’s disease (in cells, “Further exploration of the mechanism through kinetic studies and molecular modelling confirmed that compound 13 could interact with both the CAS and the PAS of AChE. These findings suggested that harmine derivatives hold great potential as dual – targeted candidates for treating AD.“)
Perspectives/Opinions
- Psychedelic treatments are speeding towards approval – but no one knows how they work (commentary/news feature)
- The remarkable reimagining of psilocybin (letter to the editor)
- Can research on entactogens contribute to a deeper understanding of human sexuality? (perspective/review)
- How Should the FDA Evaluate Psychedelic Medicine? (perspective)
- Drug-induced psychiatric disorders: A pharmacovigilance update (perspective/safety, covers ketamine)
- Novel therapeutic approaches to treat neuroinflammation in the central nervous system (editorial, covers ketamine)
Reviews
- Ketamine for Major Depressive Disorder (review/academic book chapter)
- Psilocybin and Other Classic Psychedelics in Depression (review/academic book chapter)
- Synergistic psychedelic – NMDAR modulator treatment for neuropsychiatric disorders (review, combination of ketamine and classical psychedelics)
- Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans (review, “The integration of metabolomics and pharmacokinetics for investigating the molecular interaction between psychedelics and multiple targets may open new avenues in understanding the therapeutic role of psychedelics.“)
- The Therapeutic Potential of Amphetamine-like Psychostimulants (review, covers MDMA)
- Ancient medicine for a modern disease: traditional Amazonian medicine to treat substance use disorders (review, look at Takiwasi Center’s program)
- Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression (review, TMS combined with ketamine for depression)
- Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies (review, “[W]e explore AD-like behavioral, synaptic, and molecular action of RAAs such as ketamine, scopolamine, and psilocybin, in combination with mGlu2/3 receptor antagonists.“)
- Psychedelic Drugs And Psychology (review)
Other
- Preliminary Evaluation of a Web-Based International Journal Club for Ketamine in Psychiatric Disorders: Cross-Sectional Survey Study (survey study on journal club for those using ketamine medically, “The journal club successfully reached its intended audience and developed into a web-based community. The majority of the participants were satisfied with the format and found it impactful.“)
- Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland (survey, article in Icelandic, “The use of mind-expanding hallucinogens in the treatment of mental illnesses is still not timely in the opinion of these professions, but the education of health professionals about the nature and consequences of their use needs to be strengthened in light of the increased interest in the substances in this country.“)
- Mental health facilities with ketamine infusion therapy in the United States in 2020: Co-location of dual diagnosis mental health and substance use disorder treatment (study on ketamine clinics, n=134 in the study, in the US)
- Efficacy of insula deep repetitive transcranial magnetic stimulation combined with varenicline for smoking cessation: A randomized, double-blind, sham controlled trial (TMS for smoking cessation, alternative to psychedelic treatments)
- Membrane Permeation of Psychedelic Compounds (computational study)
- Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports (analysis of trip report to further nail down the ‘ineffable’ mystical experience)
- A network model of the modulation of gamma oscillations by NMDA receptors in cerebral cortex (computational model, “We conclude that NMDA antagonists induce an increased excitability state, which may or may not produce gamma oscillations, but the response to external inputs is exacerbated, which may explain phenomena such as altered perception or hallucinations.”)
- National network of depression centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder (statement on insurance coverage of ketamine treatment for depression (TRD))
- Establishing an esketamine clinic in Australia: Practical recommendations and clinical guidance from an expert panel (on esketamine clinics in Australia, “Guidance presented in this paper should assist Australian clinicians to set up an esketamine clinic, and provide practical advice on the infrastructure and clinical requirements for treatment of patients with this agent.”)
- Ketamine for Traumatic Assault-Induced Depression: A Case Report (n=1, case report, ketamine for trauma/depression)
- Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study (n=1, case study, “We found a strong correlation between the experienced ASCs during ketamine infusions and the antidepressant effect: the stronger the ASCs overall, the stronger the resulting antidepressant effect.“)
- Hallucinating hallucinogens (essay, AI x novel psychoactive substances)
- False or Misleading Claims in Online Direct-to-Consumer Ketamine Advertising in Maryland (false/misleading advertising for ketamine)
- A Psychometric Evaluation of the Dutch Revised Mystical Experience Questionnaire (Dutch version of MEQ)
- Psilocybin therapy to reduce depression following a terminal diagnosis (poster presentation)
- Effect of single intravenous injection of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial (n=120, esketamine for PPD, found significant effect)
- Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms (HPPD x personality traits)